There was good and somewhat bad news that ACAD announced today. First the somewhat bad news. The company is delaying the filing of their new drug application with the FDA to the first quarter of 2015, from previously the end of 2014. They stressed that the delay is not an FDA issue, but more an internal issue of gathering all the pieces, for a well planned filing. So the company is losing about three months by delaying this filing, not a big picture game changer...
The new information that we have not heard before, was the marketing research the company has been working on over the last year. The research is below.
The new information that we have not heard before, was the marketing research the company has been working on over the last year. The research is below.
- 11,000 U.S. PDP treating physicians, mostly Neurologist
- 1 million Parkinson's Disease patients
- 400,000 thousand patients with PDP
- 50% have disruptive disturbances, (think sleep, or agitation/aggression (my notes)
- Reimbursement Payee is positive on the drug, (commercial, medicaid)
- Pricing of Nuplazid similar to Abilify 20 mg at $13,000 / Wholesale Acquisition Cost (WAC) annually.
Thank you for reading.
No comments:
Post a Comment